As of Jan. 28, all 10 of the facility’s manufacturing lines are back online with production capacity fully restored, according to a Feb. 17 news release from the company. The plant is now focused on rebuilding inventory to meet the customer and patient needs.
Baxter said it will continue to increase allocation levels across impacted product groups and will continue to communicate updates on production levels directly to customers.
A growing number of pharmaceutical companies are sharing plans to ramp up domestic manufacturing capacity amid recent tariffs imposed by…
DHL Express announced a temporary suspension of business-to-consumer shipments valued over $800 to private individuals in the U.S., effective April…
The FDA has issued a safety warning regarding a potentially high-risk issue involving certain BD PowerPICC Intravascular Catheters. The affected…
Comments are closed.
